Lenalidomide+obinutuzumab active in pretreated follicular lymphoma

  • Morschhauser F, et al.
  • Lancet Haematol.
  • 8 Jul 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Lenalidomide+obinutuzumab induction and maintenance was well tolerated and effective in relapsed/refractory follicular lymphoma, even among patients with early relapse.

Why this matters

  • Patients in this study had no other efficacious treatment options.

Study design

  • Phase 2 study to investigate obinutuzumab+lenalidomide induction and maintenance in patients with relapsed/refractory follicular lymphoma.
  • 89 patients were recruited; 88 patients were in the safety population; 86 patients were evaluable for efficacy.
  • Patients had received ≥1 prior rituximab-containing regimen.
  • 27% of patients had experienced early disease progression (within ≤24 months of initial diagnosis).
  • Funding: Lymphoma Academic Research Organisation; Celgene; Roche.

Key results

  • Best response during induction: 81% (95% CI, 72%-89%).
  • Response at end of induction: 79% (95% CI, 69%-87%).
  • Best response during treatment: 84% (95% CI, 74%-91%).
  • Complete response: 27%.
  • Complete unconfirmed response: 12%.
  • Partial response: 41%.
  • In post hoc analysis, overall responses were numerically comparable in patients with early vs later relapse.
  • 2-year outcomes:
    • PFS: 65% (95% CI, 54%-74%).
    • OS: 87% (95% CI, 78%-93%).
  • Duration of response: 70% (95% CI, 57%-79%).
  • Most common grade 3-4 adverse event included: neutropenia (43%), thrombocytopenia (14%).

Limitations

  • No central radiology review.